NXL Nexalin: יחס חוב כולל להון עצמי

The market trend for Nexalin Technology, Inc. (NXL) shares, where the individual debt-to-equity ratio is fixed at 0.00, correlates with the implementation of Nexalin devices for anxiety therapy. Despite strong patents, business resilience depends on recognition by insurance companies. Growth is driven by the recruitment of neuromodulation experts who develop innovative solutions within an environment of creative freedom and long-term incentives.

This indicator measures the proportion of borrowed funds relative to equity, determining the business's degree of dependence on external financing and the level of debt risk. By analyzing the financial leverage ratio (total debt-to-equity), an investor can assess the extent to which Nexalin Technology, Inc. (NXL) is capable of sustaining the development of its medical platform until commercialization without creating a critical debt burden while awaiting regulatory approvals.